Tranquillizers in Mental Deficiency: Hydroxyzine

1957 ◽  
Vol 103 (433) ◽  
pp. 855-857 ◽  
Author(s):  
Michael Craft
Keyword(s):  
Clinical Trial ◽  
Mental Deficiency ◽  
Toxic Effects ◽  
Low Grade ◽  
Double Blind ◽  
High Incidence ◽  
Mental Defectives

This paper reports a double-blind type of clinical trial with hyperactive low-grade mental defectives. Chlorpromazine has previously been used with this group but a high incidence of toxic effects has been noted (McColl (1)). Reports on reserpine have been conflicting but a careful trial by Kirk and Bauer (2) reports the action of this drug if anything to be detrimental.

HYPOTONIC CEREBRAL PALSY IN MENTAL DEFECTIVES

PEDIATRICS ◽  
1952 ◽  
Vol 9 (2) ◽  
pp. 204-211
Author(s):  
HERMAN YANNET ◽  
FRANK HORTON
Keyword(s):  
Cerebral Palsy ◽  
Mental Deficiency ◽  
Relative Importance ◽  
Pathologic Process ◽  
High Incidence ◽  
Convulsive Disorders ◽  
Mental Defectives ◽  
Clinical Pictures ◽  
Mental Defect

The relative importance of the hypotonic type of cerebral palsy among the mentally defective is stressed. This type of cerebral palsy manifests itself in either of three clinical pictures with some overlapping, namely, atonic, ataxic and athetoid. The etiology is variable in each of these groups and may be effective in either the prenatal, paranatal or postnatal periods. The severity of the mental defect, the high incidence of convulsive disorders, and the tendency toward microcephaly point towards the widespread nature of the pathologic process regardless of etiology. The syndrome of atonic diplegia, as herein described, is probably invariably associated with the more severe degrees of mental deficiency.

scholarly journals Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial

2021 ◽  
Author(s):  
Maria Antonietta Nettis ◽  
Giulia Lombardo ◽  
Caitlin Hastings ◽  
Zuzanna Zajkowska ◽  
Nicole Mariani ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Rating Scale ◽  
Antidepressant Treatment ◽  
Randomised Clinical Trial ◽  
Peripheral Inflammation ◽  
Low Grade ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Double Blind ◽  
Resistant Depression

AbstractThis study aimed to investigate the role of baseline levels of peripheral inflammation when testing the efficacy of antidepressant augmentation with minocycline in patients with treatment-resistant depression. We conducted a 4-week, placebo-controlled, randomised clinical trial of minocycline (200 mg/day) added to antidepressant treatment in 39 patients selected for elevated levels of serum C-reactive protein (CRP ≥ 1 mg/L), n = 18 randomised to minocycline (M) and n = 21 to placebo (P). The main outcome was the change in Hamilton Depression Rating Scale (HAM-D-17) score from baseline to week 4, expressed both as mean and as full or partial response, in the overall sample and after further stratification for baseline CRP≥3 mg/L. Secondary outcomes included changes in other clinical and inflammatory measures. Changes in HAM-D-17 scores and the proportion of partial responders did not differ between study arms. After stratification for CRP levels <3 mg/L (CRP−) or ≥3 mg/L (CRP+), CRP+/M patients showed the largest changes in HAM-D-17 scores (mean ± SD = 12.00 ± 6.45) compared with CRP-/M (2.42 ± 3.20, p < 0.001), CRP+/P (3.50 ± 4.34, p = 0.003) and CRP−/P (2.11 ± 3.26, p = 0.006) patients, and the largest proportion (83.3%, p = 0.04) of partial treatment response at week 4. The threshold point for baseline CRP to distinguish responders from non-responders to minocycline was 2.8 mg/L. Responders to minocycline had higher baseline IL-6 concentrations than non-responders (p = 0.03); IFNγ was significantly reduced after treatment with minocycline compared with placebo (p = 0.03). Our data show some evidence of efficacy of add-on treatment with minocycline in MDD patients but only in those with low-grade inflammation defined as CRP ≥3 mg/L.

A Long-Term Clinical Trial with a Non-Steroidal Oestrogen

1975 ◽  
Vol 3 (3) ◽  
pp. 183-188
Author(s):  
A P Camilleri ◽  
Rose Galea ◽  
M Dolores Falzon
Keyword(s):  
Clinical Trial ◽  
Toxic Effects ◽  
Double Blind ◽  
Double Blind Clinical Trial

A double-blind clinical trial has been carried out with a new non-steroidal oestrogenic substance (P1496). Taken cyclically over a period of 15 months or more the drug appears to be well tolerated and apparently free of toxic effects. In the dosage used the drug is clinically effective as an oestrogen analogue.

Double blind placebo controlled clinical trial of homoeopathic medicines in HIV infection

1998 ◽  
Vol 87 (2) ◽  
pp. 86-88
Author(s):  
D P Rastogi ◽  
V P Singh ◽  
Vikram Singh ◽  
S K Dey ◽  
K Rao
Keyword(s):  
Clinical Trial ◽  
Hiv Infection ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document